Ibrutinib Improves Outcomes in CLL/SLL

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

In this video, Asher A. Chanan-Khan, MD, of the Mayo Clinic in Jacksonville, Florida, discusses a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

The trial’s results (abstract LBA7005) were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29–June 2 in Chicago.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Related Content
acute lymphoblastic leukemia

Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL

Ariana Pelosci
December 7th 2025
Article

Clinical efficacy and response rates were increased with blinatumomab/ponatinib vs chemotherapy/imatinib for patients with Ph+ ALL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Investigators reported fewer dose reductions due to treatment-emergent adverse effects with pirtobrutinib vs ibrutinib in the phase 3 BRUIN CLL-314 trial.

Noninferior Responses Occur With Pirtobrutinib vs Ibrutinib in CLL

Jason M. Broderick
December 7th 2025
Article

Investigators reported fewer dose reductions due to treatment-emergent adverse effects with pirtobrutinib vs ibrutinib in the phase 3 BRUIN CLL-314 trial.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Increased Dose of Axatilimab Noted as Tolerable in cGVHD

Kristie L. Kahl
December 6th 2025
Article

“Overall, these findings support the safety and feasibility of axatilimab at a dose of 0.6 mg/kg monthly,” said Nosha Farhadfar, MD.

Even among Black patients with sufficient social support for clinical trial enrollment, there is inequity related to accessing allogenic transplantation.

Poorer Outcomes Observed for Black Patients Undergoing Chemotherapy for AML

Bridget Hoyt
December 6th 2025
Article

Even among Black patients with sufficient social support for clinical trial enrollment, there is inequity related to accessing allogenic transplantation.